Pulmonary arterial hypertension (PAH) represents a challenging condition characterized by progressive vascular remodeling, ultimately leading to right heart failure and diminished quality of life. Despite advancements in therapy, there remains an unmet need for effective treatments. In recent years, tumor growth factor (TGF) β pathway modulators have emerged as a potential game-changer in the management of PAH. Sotatercept, a novel fusion protein, acts as a ligand trap for members of the TGFβ superfamily, thereby modulating the dysregulated signaling pathways implicated in PAH pathogenesis. This talk will delve into the underlying mechanisms of sotatercept's action, elucidating its role in mitigating pulmonary vascular remodeling and right ventricular hypertrophy. Furthermore, clinical evidence supporting the efficacy and safety of sotatercept in PAH therapy and its potential as a disease-modifying agent will be mentioned in this talk. Additionally, it underscores the need for further investigation to elucidate the long-term effects and potential combination therapies involving sotatercept.